Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

285 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Evaluation of the Aggressive-Variant Prostate Cancer Molecular Signature in Clinical Laboratory Improvement Amendments (CLIA) Environments.
Viscuse PV, Slack-Tidwell RS, Zhang M, Rohra P, Zhu K, San Lucas FA, Konnick E, Pilie PG, Siddiqui B, Logothetis CJ, Corn P, Subudhi SK, Pritchard CC, Soundararajan R, Aparicio A. Viscuse PV, et al. Among authors: siddiqui b. Cancers (Basel). 2023 Dec 14;15(24):5843. doi: 10.3390/cancers15245843. Cancers (Basel). 2023. PMID: 38136389 Free PMC article.
The Next Decade of Immune Checkpoint Therapy.
Sharma P, Siddiqui BA, Anandhan S, Yadav SS, Subudhi SK, Gao J, Goswami S, Allison JP. Sharma P, et al. Cancer Discov. 2021 Apr;11(4):838-857. doi: 10.1158/2159-8290.CD-20-1680. Cancer Discov. 2021. PMID: 33811120 Review.
Durable responses in patients with genitourinary cancers following immune checkpoint therapy rechallenge after moderate-to-severe immune-related adverse events.
Siddiqui BA, Gheeya JS, Goswamy R, Bathala TK, Surasi DS, Gao J, Shah A, Campbell MT, Msaouel P, Goswami S, Wang J, Zurita AJ, Jonasch E, Corn PG, Aparicio AM, Siefker-Radtke AO, Sharma P, Subudhi SK, Tannir N. Siddiqui BA, et al. J Immunother Cancer. 2021 Jul;9(7):e002850. doi: 10.1136/jitc-2021-002850. J Immunother Cancer. 2021. PMID: 34326169 Free PMC article.
Evaluation of Technology-Enabled Monitoring of Patient-Reported Outcomes to Detect and Treat Toxic Effects Linked to Immune Checkpoint Inhibitors.
Msaouel P, Oromendia C, Siefker-Radtke AO, Tannir NM, Subudhi SK, Gao J, Wang Y, Siddiqui BA, Shah AY, Aparicio AM, Campbell MT, Zurita AJ, Shaw LK, Lopez LP, McCord H, Chakraborty SN, Perales J, Lu C, Van Alstine ML, Elashoff M, Logothetis C. Msaouel P, et al. JAMA Netw Open. 2021 Aug 2;4(8):e2122998. doi: 10.1001/jamanetworkopen.2021.22998. JAMA Netw Open. 2021. PMID: 34459906 Free PMC article.
Combined CTLA-4 and PD-L1 blockade in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer is associated with increased myeloid and neutrophil immune subsets in the bone microenvironment.
Subudhi SK, Siddiqui BA, Aparicio AM, Yadav SS, Basu S, Chen H, Jindal S, Tidwell RSS, Varma A, Logothetis CJ, Allison JP, Corn PG, Sharma P. Subudhi SK, et al. J Immunother Cancer. 2021 Oct;9(10):e002919. doi: 10.1136/jitc-2021-002919. J Immunother Cancer. 2021. PMID: 34663638 Free PMC article.
285 results